Furthermore, by integrating gene expression, ex vivo drug response, and clinical response data, we aimed to determine whether S100 expression could guide treatment response, especially to established myeloma drugs, including proteasome inhibitors. This evidence concerns the gene S100B and plasma cell myeloma.